On April 15, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ( Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ) disclosed the 2021 annual report. During the reporting period, the listed company achieved an operating revenue of 8.022 billion yuan, a year-on-year increase of 23.2%; The net profit attributable to the parent company was 2.431 billion yuan, a year-on-year increase of 45.46%; The basic earnings per share is 4.03 yuan, and a cash dividend of 12.1 yuan (including tax) is proposed for every 10 shares.
In 2021, China Meheco Group Co.Ltd(600056) manufacturing industry has a good overall development trend. According to the data of the National Bureau of statistics, in 2021, the China Meheco Group Co.Ltd(600056) Manufacturing Industrial Enterprises above Designated Size achieved an operating revenue of 292885 billion yuan, an increase of 20.1% year-on-year; The total profit was 627.14 billion yuan, a year-on-year increase of 77.9%. In the environment of policy wave sweeping the pharmaceutical industry, the dividend policy of traditional Chinese medicine industry comes one after another.
From the perspective of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , adhere to making Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , expand Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) brand Angong Niuhuang Pill and strengthen Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) cosmetics; At the same time, actively look for suitable targets and steadily promote extension M & A, so as to realize the high-quality leapfrog development of the company.
In 2021, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) won the “Hurun brand list” with a brand value of 51 billion yuan, and ranked first in the list of medical and health brand values. As of December 31, 2021, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) assets totaled 12.495 billion yuan, and shareholders’ equity attributable to the parent company was 9.705 billion yuan.
In terms of R & D, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) will continue to improve the layout of R & D planning, form a R & D pipeline with brand characteristics, focus on Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) increasing new functions for the treatment of liver cancer and Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) preventing recurrence after liver cancer eradication, promote clinical progress, and start the renewal of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) traditional Chinese medicine protection varieties, speed up the R & D of new drug varieties under research, combined with tumor Cardiovascular and cerebrovascular diseases, digestive system diseases and other clinical dominant diseases of traditional Chinese medicine, and deeply explore the clinical value and functional characteristics of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) Angongniuhuang pill, compound Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) ointment, compound Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) hemorrhoids ointment and yindanpinggan capsule.
From the market perspective, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) will focus on large varieties according to the current production capacity of the company, strengthen the promotion of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) capsule, do a good job in the marketing of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) OTC version, vigorously promote the expansion of sales scale of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) brand Angong Niuhuang Pill, and strive to achieve a new record in the sales of single products of “two ointments and one tablet”, Yindan Pinggan capsule, Chuanbei Qingfei syrup and other series products.
Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) at the end of last month, the announcement of earnings forecast for the first quarter of 2022 was disclosed, and the net profit is expected to reach 678 million yuan to 701 million yuan, with a year-on-year increase of 20% to 24%.
In view of the earnings forecast, Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) said that it was mainly because the company strengthened market planning and expanded sales channels to increase the sales of Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) series of core products. Guosheng Securities Research Report believes that the above performance is in line with expectations, and Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) series is expected to maintain rapid growth.
